Has Reynaldo Tan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,265 in general payments to Reynaldo Tan, MD across 14 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Reynaldo Tan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Reynaldo Tan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Reynaldo Tan, MD

Nephrology · Brooklyn, NYNPI 1053343731

Payments from drug & device makers

$1,265in general payments, 2019–2025

Across 14 payments — averaging $90.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$827
Novo Nordisk$250
Lilly USA, LLC$93
Mallinckrodt Enterprises LLC$75
Gilead$20

What the payments were for

Food & beverage$1,19094%
Education$756%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	8	$827
Novo Nordisk	2	$250
Lilly USA, LLC	2	$93
Mallinckrodt Enterprises LLC	1	$75
Gilead	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

FARXIGA$616
Ozempic$250
FASENRA$115

How this compares

$1,265 in reported general payments places this provider in the 55th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York →

Medicare billing

Part B allowed, 2024

$424,542

Medicare patients

640

Services billed

3,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JardianceEmpagliflozin	604	$572,108
FarxigaDapagliflozin Propanediol	441	$360,152
OzempicSemaglutide	235	$280,662
KerendiaFinerenone	223	$202,040
JanuviaSitagliptin Phosphate	190	$187,946
TrulicityDulaglutide	101	$145,422
VelphoroSucroferric Oxyhydroxide	42	$140,754
LokelmaSodium Zirconium Cyclosilicate	159	$136,961
VeltassaPatiromer Calcium Sorbitex	93	$114,207
EliquisApixaban	88	$101,982
MounjaroTirzepatide	64	$89,413
XphozahTenapanor Hcl	23	$65,460
Sevelamer Carbonate	195	$52,118
EntrestoSacubitril/Valsartan	62	$51,927
TradjentaLinagliptin	34	$30,790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AstraZenecaFarxiga, Lokelma	$827	$497,113600 claims
Novo NordiskOzempic, Rybelsus	$250	$308,807248 claims
Lilly USA, LLCTrulicity, Mounjaro	$93	$234,835165 claims
GileadVemlidy	$20	$14,97811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 935 nephrology providers in New York.

Other nephrology in Brooklyn

Subodh SaggiBrooklyn$419K
Alexander SwanBrooklyn$172K
Joji TokitaNew York$8.4M
Krzysztof KirylukNew York$6.7M
David BernardNew York$6M
Andrew BombackNew York$3.4M
Pietro CanettaNew York$3.2M
Robert LynnBronx$2M
Jodumutt BhatMaspeth$1.5M
Gerald AppelNew York$1.5M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →